Q-omics provides the consensus-scored CHTOP profile across patient tissues and cancer cell-line models. CHTOP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHTOP is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CHTOP RNA expression shows 20,396 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where CHTOP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHTOP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHTOP survival associations across molecular data types. CHTOP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHTOP RNA expression–survival associations across cancer types. High CHTOP expression shows unfavorable associations in ACC, MESO, KIRP, LIHC, CESC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHTOP RNA expression.
This table summarizes CHTOP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CHTOP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHTOP shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, HNSC, LIHC and STAD. The COAD box plot shows higher CHTOP RNA expression in tumor versus normal tissue (log2 FC = +0.860, t-test p < 0.001).
This table shows molecular features associated with CHTOP in patient tissues and cancer cell lines. In patient samples, CHTOP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHTOP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
